Physicians often tell AFib patients they should limit coffee consumption to protect their hearts. This new analysis, however, suggests that may not be necessary.
Researchers used AI-enabled software developed by Cleerly to evaluate the CCTA results of more than 6,000 patients. The software was consistently effective, identifying patients who may face an increased risk of poor outcomes.
Calcium in the coronary arteries is a known cardiac risk factor. However, new data suggest it may actually tell us more about a person's overall health than researchers previously believed.
Researchers warned that “aggressive procedural modifications” should not be necessary during TAVR to mitigate the risk of prosthesis-patient mismatch. This appears to be true for patients receiving both self-expanding and balloon-expandable TAVR valves.
Rebecca Hahn, MD, discussed key takeaways from the TRISCEND II trial for the Edwards Lifesciences Evoque TTVR valve and shared additional details related to patient selection and implanting the device.
The first patient has been enrolled in a new study of an optimized lead for LBBAP, an area with an explosion of interest in EP as a way to improve patient outcomes.
"This research should be a call to health systems, policymakers and other stakeholders to make it easier for patients—especially the most vulnerable patients—to access PAD-specific care," one cardiologist explained.
Clyde Yancy, MD, spoke with Cardiovascular Business about how the treatment of heart failure with preserved ejection fraction (HFpEF) has evolved in recent years.
Experts recently uncovered evidence suggesting behaviors such as undereating, binging and purging could be owed to anatomical alterations in parts of the brain.
Results from the world’s largest prospective artificial intelligence study revealed the system could significantly benefit breast cancer screening programs.
The new atrial shunt from Alleviant Medical was designed to treat heart failure without leaving a permanent implant behind. The FDA granted the technology its breakthrough device designation and approved additional research.
